Article info
Therapeutics
Original article
Longitudinal evaluation of SMN levels as biomarker for spinal muscular atrophy: results of a phase IIb double-blind study of salbutamol
- Correspondence to Professor Francesco Danilo Tiziano, Institute of Genomic Medicine, Catholic University, Roma 00168, Italy; francescodanilo.tiziano{at}unicatt.it
Citation
Longitudinal evaluation of SMN levels as biomarker for spinal muscular atrophy: results of a phase IIb double-blind study of salbutamol
Publication history
- Received May 11, 2018
- Revised November 10, 2018
- Accepted November 30, 2018
- First published December 28, 2018.
Online issue publication
April 25, 2019
Article Versions
- Previous version (28 December 2018).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.